DOE will invest more than $500 million and Biohub $500 million over five years in open cell data for AI models, under a pact with NIH. Biohub puts the whole effort at $1.8 billion, a total that counts NIH-coordinated datasets built with earlier federal money.
Publishers:biohub.org · energy.gov
Reality
- Evidence40
- Adoption
- Not scored
- Hype gap+30
- Incentives75
- Confidence60
Alphabet's Isomorphic Labs is in funding talks at a $40 billion valuation. Crypto Briefing put its prior mark near $17.5 billion, so the ask more than doubles the price of a drug designer that has yet to dose a patient.
Perspective Coverage
6 publishers
- Builder
- Builder 26%
- Operator
- Operator 17%
- Investor
- Investor 57%
Reality
- Evidence55
- Adoption25
- Hype gap+45
- Incentives55
- Confidence55
Meta, Google DeepMind and Isomorphic Labs put $300 million into Biohub's $1.8 billion Virtual Biology Initiative and get the data before the public does. Startups that sell proprietary cell data will now be priced against a free dataset that their best-funded rivals see first.
Perspective Coverage
13 publishers
- Builder
- Builder 41%
- Operator
- Operator 31%
- Investor
- Investor 28%
Reality
- Evidence66
- Adoption18
- Hype gap+35
- Incentives72
- Confidence62
The $20mn round buys roughly 0.53 per cent of the company, and no product exists yet. Read the number as a reference price for pre-revenue bio-AI, not a verdict on the science.
Reality
- Evidence45
- Adoption3
- Hype gap+60
- Incentives65
- Confidence62
Brin shapes Gemini's model sizes and release windows from a converted microkitchen
Business Insider, citing eight current and former employees, reports that Google's cofounder holds no executive title while making technical calls on Gemini from a desk the new DeepMind SVP shares. Google declined to comment.
Reality
- Evidence40
- Adoption
- Not scored
- Hype gap+14
- Incentives62
- Confidence38
Academics get all 9 billion single-base predictions through a browser at no cost, while commercial users wait on a Google Cloud licence whose terms DeepMind has not published, including for its own sister company.
Reality
- Evidence54
- Adoption30
- Hype gap+24
- Incentives78
- Confidence58
IITGN clones the four stigma genes behind toria's rejection of its own pollen
The work is careful basic genetics: cloned sequences, predicted protein folds, and one gene switched off at a time. Whether it touches India's 56% edible oil import share depends on breeding that has not happened yet.
Reality
- Evidence58
- Adoption12
- Hype gap+30
- Incentives68
- Confidence55
Insilico credits its AI with a drug discovery. The patent credits five humans.
Only people can be inventors under US law, so the file on an AI-derived molecule has to show human contribution. Teams that do not document it are building patents someone can challenge.
Reality
- Evidence56
- Adoption44
- Hype gap+22
- Incentives66
- Confidence58
buildConfirmed2 publishers The startup opened a robotic "human data center" near San Francisco on the thesis that AI drug discovery is limited by causal human experiments, not model capacity.
Reality
- Evidence44
- Adoption31
- Hype gap+24
- Incentives71
- Confidence56
Vivodyne says the AI drug bottleneck is human tissue data, not model capability
The startup opened what it calls the world's largest human data center last week. Its diagnosis of the field is testable; most of the evidence for its own machines is self-reported.
Reality
- Evidence34
- Adoption27
- Hype gap+32
- Incentives76
- Confidence44
CoreWeave's $104bn backlog is now a margin question, not a demand question
Management says scale is starting to show up as operating leverage. The release as supplied gives a backlog, power figures and more than $14bn of fresh capital, but no margin numbers.
Publishers:investors.coreweave.com
Reality
- Evidence42
- Adoption71
- Hype gap+32
- Incentives88
- Confidence55